Viemed Healthcare, Inc.

VMD · Nasdaq · ·

Vergleichen

9,19 $+0,8 %Schluss 13. Nov.

Zahlen bis 30. September 2026, aus dem 10-Q vom 4. November 2026

1W: +0,7 %
1M: -5,2 %

Just reported

Q3 2026 results

From Viemed Healthcare's results release of 4. November 2026; its quarterly report has since been filed.

Revenue
Actual
80,7M $
+12 % y/y
+3,3 % q/q
Guided
—
No guide given
EPS, GAAP
Actual
0,11 $
+22 % y/y
+57 % q/q
Guided
—
No guide given
Operating income, GAAP
Actual
7M $
+23 % y/y
+56 % q/q
Guided
—
No guide given

Company outlook

Full year 2026

Revenue316M $ – 320M $+18 % y/y Raised +0,3 %

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Viemed Healthcare is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Medical Devices

Graded A or B and worth $2B or more: A first, then the largest.

All 133 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Vollständige Abschlüsse →

Gebaut aus den eigenen Einreichungen von Viemed Healthcare, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.

Viemed Healthcare, Inc.

Viemed Healthcare, Inc.

Q3 2026 results

Revenue

EPS, GAAP